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INTRODUCTION
             
  Leukemia has been the focus of immense research and progress over the last 
century. The most common subtype, acute lymphoblastic leukemias (ALL) 
accounts for 75% - 80% of all childhood leukemias, with acute myeloid leukemia 
comprising 20% and chronic myeloid leukemia around 2%. Survival rates for ALL 
have improved dramatically  with a current five-year overall survival rate 
estimated at 78 to 85 percent.1,2,3,4 Improvement in survival is due to treatment of 
a large number of children on sequential standardized research protocols. Eighty - 
ninety percent of children with newly diagnosed ALL participate in such trials, the 
goals of which are to improve clinical outcomes while minimizing acute toxicities 
and late-occurring adverse events.  Event-free survival (EFS) rates for ALL have 
also steadily improved since the 1980s. The overall five-year EFS for childhood 
ALL currently approaches 80 percent in the developed world, and the ten-year 
EFS is about 60 percent 5. The five and estimated ten-year survival rates for 
patients diagnosed from 2000 to 2004 were 88 and 84 percent, respectively 6. The 
ten-year survival rate for children diagnosed in the 2005 to 2009 period is 
estimated to be 88 percent.
               In contrast, in the developing world, cure rates are less than 35 percent 
7.The main reasons include late presentation , difficulty in 
accessing  health  services  ,  poverty  ,  non  compliance  to  therapy  and  lack  of 
dedicated paediatric oncology units.
                 The population of India recently exceeded a billion people. Almost 50% 
are less than 25 years of age. Although complete data for India are not available, 
population-based  data  from  various  Indian  cancer  registries  suggest  that 
approximately  10,000 new cases  of  acute  lymphoblastic  leukaemia (ALL) occur 
each year  in the <25 year age  group.  A small  percentage  of  these  patients  are 
adequately  treated,  and the  majority  die  from the  disease.  This  contrasts  with 
present cure rates of over 80% in Western countries.  India faces  problems as in 
all other developing countries which includes paucity of cancer treatment facilities, 
lack of human and physical resources required for effective management (both of 
which lead to lack of access to effective medical care),  poverty and low level of 
education of the population. Also included are delay in diagnosis and consequent 
presentation with more advanced disease and high rate of abandonment of therapy 
with subsequent loss to follow-up. 
                Malnutrition is an adverse prognostic factor in the outcome of treatment 
in patients with acute lymphoblastic leukemia. Undernourished children do poorly 
as compared with well nourished children. The reasons cited are many and include 
malnourishment leading to a 
diminished  bone  marrow  reserve  resulting  in  delivery  of  suboptimal  doses  of 
maintenance chemotherapy (less  than that calculated according to body surface 
area). 
                 Depletion of nutritional reserves and significant weight loss can lead to 
an  increased  risk  of  morbidity,  reduced  chemotherapy  response,  and  shorter 
survival in patients with cancer. Weight loss and malnutrition are recognized to 
result from multifactorial processes, which if assessed and managed appropriately 
may lead to improved treatment outcome.
              The prevalence of malnutrition in India is 45.9% as per National Family 
Health Survey of India 3(2005 – 2006). We would expect the same prevalence, if not 
higher, in children presenting with leukemia. With this in mind, the plan for our 
study is to compare the outcome of well nourished versus undernourished children 
who are treated for ALL in the hematology  unit at the Institute of Child Health.
w
REVIEW OF LITERATURE
              The leukemias are the most common malignant neoplasms in childhood, 
accounting for about 40% of all malignancies that occur in children less than 15 years of 
age .  Acute lymphoblastic  leukemia accounts  for  about 75 % of cases of  childhood 
leukemia, acute myelogenous leukemia for about 20%, chronic myelogenous leukemia 2 
-3 % and juvenile chronic myelogenous leukemia about 1 – 2%.. 
                Childhood ALL was the first disseminated cancer shown to be curable and 
consequently  has  represented  the  model  malignancy  for  the  principles  of  cancer 
diagnosis, prognosis and treatment. It is actually considered as a heterogenous group of 
malignancies with a number of distinctive genetic abnormalities that result in varying 
clinical behaviours and responses to therapy. Appropriate risk assessment has over the 
years  been  found  to  be  the  most  important  factor  in  the  selection  of  therapy.  The 
outcome of ALL is dependent on a number of factors. The most crucial factors include 
the  clinical  features,  cytogenetics  of  the  leukemic  cells,  pharmacodynamics, 
pharmacogenetics and early treatment response. It  is the research on the interplay of 
these factors and the use of risk adapted treatment protocols which has resulted in nearly 
80% survival at the turn of the millennium. 
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Outcome of Acute lymphoblastic leukemia 
 In Developed countries
              The prognosis of childhood acute lymphoblastic leukemia (ALL) has improved 
greatly in the past 40 years. Current literature report on  a long-term event free survival 
(EFS) of about 75% and overall survival(OS) of about 80% in developed countries. 
                 In the Nordic countries the 5 year event free survival of childhood ALL has 
increased from 57% to 77% in the past 2 decades and the current figures give an EFS of 
79%.10 
                  In another study done in Spain between 1989 and 2005 , 50 patients were 
analysed and the 5 yr EFS was 78% with the OS being 87.8%.11
                 Recent figures from United Kingdom using the UKALL 97/99 protocol give 
an event free survival of 78%, an improvement of nearly 8 -10% from a decade earlier.
                  In a study done in Kyushu  University, Fukoaka  Japan on 62 patients with 
ALL, the 10 yr EFS was   80.6+5  %   and the OS was 88.7+ 4% after a median follow-
up time of 9.3 years.12 
 
                  In the United States, there are approximately 2,400 children and adolescents 
younger than 20 years of age diagnosed with ALL each year .Seventy-five percent to 
80%  of  children  with  ALL  survive  at  least  5  years  from  diagnosis  with  current 
treatments  that  incorporate  systemic  therapy  (e.g.,  combination  chemotherapy)  and 
specific central nervous system (CNS) preventive therapy (i.e., intrathecal chemotherapy 
with or without cranial irradiation).13,14,15,16
In developing countries:
               More than 80% of the world’s children live in less-advantaged countries, 
where the cure rate generally does not exceed 35%. Patients with ALL in developing 
countries often present with more advanced disease. Co-morbidities such as hepatitis, 
malaria  and malnourishment  are  also  more  common,  which  may affect  the  patients' 
ability to tolerate treatment. Access to care in cancer centers or pediatric oncology units 
is much more limited in developing countries, and patients and their families often have 
to  travel  long distances  to  reach  major  hospitals  for  the  diagnosis  and/or  providing 
necessary treatment. Further, even when they reach these centers, a family's inability to 
pay for treatment due to socioeconomic factors or the lack of health insurance has a 
major  impact  upon  the  type  of  therapy  that  is  ultimately  provided  to  the  child. 
Continuation of treatment and follow-up is often difficult, again because 
of  socioeconomic  factors,  the  need to  travel  long distances,  and the  lack  of  trained 
physicians  who  can  manage  their  care  outside  the  major  cancer  center  or  pediatric 
oncology unit. This results in a high default rate.
                  In a study in China from 1998 to 2007 on 329 (203 males and 126 females) 
newly-diagnosed cases of childhood ALL,   the overall EFS  at 5 years was (68.0 ± 5.0) 
%.All the children were treated with ALL XH 99 protocol. Patients were classified into 
low risk (LR), medium risk(MR) and high risk (HR) on the basis of their presenting 
clinical features, biological features and early response to remission induction treatment. 
The EFS rates at 5 years in LR, MR and HR groups were (83.0 ± 6.0) %, (78.0 ± 14.0) 
% and (39.0 ± 10.0) %, respectively (P <0.05).19
               In a study in El Salvador done between 1994 and 1996 , 153 children with 
ALL were included. They were treated with the modified SJCRH protocol. High risk 
was defined as: DNA index < 1.16, age 12 months or younger, white blood cell count > 
or = 50 x 10(9)/L, T-cell immunophenotype, anterior mediastinal mass, central nervous 
system leukemia at diagnosis, or t(4;11), t(1;19), or t(9;22).The overall 4 yr survival 
rates were 48+ 6%. The 4-year EFS rates in patients at high-risk and standard-risk were 
46 +7% (n = 121) and 69 +15% (n = 16), respectively (P = 0.20).21
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              A study was conducted in China on 58 children with ALL between 1998 and 
2003. The 5 yr  EFS in this study was 51.3%.It was also  concluded that when compared 
with  industrialized countries, children with ALL have a  lower remission rate, a lower 
5-year EFS, and a higher mortality from sepsis.22.
                In 2009, a Chinese study on 91 children with ALL has given an EFS of 52.3 % 
at  4 years.  The treatment  related mortality  has been seen to  be 3.3% and treatment 
abandonment as 24.2%.Treatment abandonment is a major cause of treatment failure in 
China.23.
                  The causes of treatment failure in childhood acute lymphoblastic leukaemia 
are thought to differ between resource-rich and resource-poor countries. In a study in 
Honduras,168 children with ALL were analysed. Abandonment of therapy was the main 
cause of treatment failure. Treatment failure was also associated with prolonged travel 
time to treatment facility and age less than 4.5 years.24
                The National Chilean Pediatric Oncology Group, PINDA conducted a 
prospective  nonrandomized  trial   using  a  modified  version  of  the  Berlin-Frankfurt-
Munster protocol (ALL BFM 86) from June 1987, to June 1992,on  425 patients with 
ALL. Therapy was stratified by risk as standard, high and very high risk. The overall 5-
year event-free survival (EFS) rate was 60% ± 2% (SE). The 5-year EFS rate for each 
risk group 
was: SR 75%, HR 62%, VHR 28%, with a median follow-up of 6.5 years (range 4.5-9.5 
years).25
Outcome of ALL in India:
                In the 1970s, survival rates after treatment for acute lymphoblastic leukaemia 
(ALL) in children and young adults (less than 25 years) in India were poor, even in 
specialised cancer centres. 
                The earliest ALL studies in India during the 1970s were conducted at the Tata 
Memorial Hospital in Munbai and the 3 year survival has seen to be 22%. In the 1980’s 
with more aggressive therapy and improvement in supportive care the EFS at 5years had 
improved to 32%.
                There have been a few studies on the outcome of ALL in India. A multicentric 
trial  done by the International Network for  Cancer Treatment and Research where 3 
Indian hospitals: Cancer Institute , Chennai ; Tata Memorial Hospital ,Mumbai and All 
India Institute of Medical sciences, New Delhi  contributed data, a 5 year survival rate 
between 45% and 60% was seen. This includes higher rate of toxic deaths and extensive 
disease partly  attributable  to  delayed diagnosis.  It  has been felt  that  the risk factors 
defined in the western population cannot be assumed to be equally appropriate for risk 
adapted therapy in less affluent 
countries. The heterogenicity in patient population can result in significant differences in 
outcome.8
               Differences in the patient populations between the developed world and India 
has been noted. In a multicentric trial in India, total white blood cell count (WBC) was 
the only statistically significant risk factor identified in multivariate analyses. Age is 
strongly associated with outcome in Western series, but was not a risk factor for EFS in 
any of the Indian centres. Comparison of patient characteristics with published series 
from Western  nations  indicated  that  patients  from all  the  Indian  centres  had  more 
extensive  disease  at  presentation,  as  measured  by  WBC,  lymphadenopathy  and 
organomegaly. The worse outcome of treatment in Indian patients compared with recent 
Western series was probably due to the higher rate of toxic deaths in the Indian patients, 
and possibly  also  due  to  their  more  extensive  disease  –  which  is,  at  least  partly,  a 
consequence of delay in diagnosis. Differences in the spectrum of molecular subtypes 
may also have played a role. The higher toxic death rates observed are likely to have 
arisen from a combination of more extensive disease at diagnosis, co-morbidities (e.g., 
intercurrent infections),  differences in the level of hygiene achievable in the average 
home, poor access to acute care, and more limited supportive care facilities in Indian 
hospitals. Since the prevalence of individual risk factors varies in different populations . 
and over time,  their  relative importance would also be expected to vary in different 
centres and in different time periods.  These findings have important implications for the 
treatment of ALL in countries of low socioeconomic status. It cannot be assumed that 
risk  factors  defined  in  Western  populations  are  equally  appropriate  for  patient 
assignment to risk-adapted therapy groups in less affluent countries. 
               A  study was done in All India Institute of Medical Sciences from June 1992 to 
June 2002  where 250 children up to 15 years age with newly diagnosed ALL were 
included  and  were  uniformly  treated  on  MCP  841  protocol.  There  was  a  male 
preponderance (male: female-3.8: 1).The event free and disease free survival rates were 
67.5 % and 51.6% respectively.26
                 In another study done in Institute for Child Health and Hospital, Chennai 
during the period of June 1991 to December 1995, the outcome of 135 children with 
ALL  was  analysed  .  Seventy  children  (53  per  cent)  were  treated  with  a  high  risk 
protocol, 25 (17 per cent) received an intermediate risk, and 40 patients (30 per cent) 
received a standard risk protocol. Analyzing the outcome in 135 children, 34 (27 per 
cent) had event free survival (EFS) at the time of analysis; of these 41 per cent had EFS 
after 2 years of therapy, 31 per cent after 3 years and 18.7 per cent after 4 years (i.e. 1 
year after stopping 3 years of therapy). Fifty-seven 
children  (41  per  cent)  dropped out;  25  (18  per  cent)  died  due  to  sepsis.  Treatment 
obstacles  included  delay  in  diagnosis,  poor  health  education  and  facilities,  poor 
supportive care, and socio-economic problems.27
                In a retrospective analysis  in a Government Medical College in Kerala  79 
patients with  acute lymphatic leukemia  treated  from January 1990 to June 2006   were 
analysed. Of the 73 patients who completed treatment, 23 survived (36%); 20 had event-
free survival more than 5 years after remission.28
               In a study done in Vellore, three hundred and seven children (1-14 years) with 
acute lymphoblastic leukemia (ALL) were treated with a modified BFM protocol 76/79 
between 1985 and 2003. Treatment outcome and prognostic factors were evaluated. The 
median  event  free  survival  (EFS)  was  114  months.  The  estimated  5  year  overall 
survival, EFS and disease free survival was 59.8%, 56%, and 53.9%, respectively.29
               In a study done in  Cancer Institute, Chennai from 1990 to 2001,345 children 
with  ALL  were  diagnosed  and  their  survival  rates  were   calculated.  The  absolute 
survival  rates  at  1  ,  3  ,  5  and  10  years  were  58.6%,40.5%,36.3%  and  29.8% 
respectively.8
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              The factors predicting the outcome to treatment of children with ALL    include: 
age  ;  sex  ;  race  ;  liver  and/or  spleen  enlargement  ;  morphology  (French-American 
British Cooperative Group (FAB)) of the blast-cells ;  immunologic phenotype of the 
blast-cells ,  white  blood cell  count (BC) at diagnosis ;  platelet count at  diagnosis ; 
central  nervous  system  CNS)  leukaemic  infiltration  at  diagnosis  ;  glucocorticoid 
receptors in the blast-cells ; Periodic acid shift (PAS) reactivity of the blast cells; time to 
achieve complete remission ; chromosomal abnormalities , number of blast cells in DNA 
synthesis phase .9Malnutrition has also been quoted as adverse prognostic factor in ALL 
especially in the developing countries
Nutrition and cancer :
     Malnutrition is found in 10 -50-% of children with cancer in industrialized 
countries. In developing countries a large proportion of the normal pediatric population 
is undernourished and children frequently present late with advanced disease.
               Cancer-associated malnutrition can result from local effects of a tumour, the 
host response to the tumour and anticancer therapies. Cancer patients often have reduced 
food intake due to systemic effects of the disease, local tumour effects, psychological 
effects or adverse effects of treatment. In addition alterations in nutrient metabolism and 
resting 
energy  expenditure  (REE)  may  also  contribute  to  nutritional  status.  Several  agents 
produced by the tumour directly, or systemically in response to the tumour, such as pro-
inflammatory  cytokines  and hormones,  have  been  implicated  in  the  pathogenesis  of 
malnutrition  and cachexia.  The  consequences  of  malnutrition  include  impairment  of 
immune  functions,  performance  status,  muscle  function,  and  quality  of  life.  Also, 
responses  to  chemotherapy  are  decreased,  chemotherapy-induced  toxicity  and 
complications  are  more  frequent  and  severe,  and  survival  times  are  shortened. 
Depression,  fatigue  and  malaise  also  significantly  impact  on  patient  well-being.  In 
addition,  cancer-related  malnutrition  is  associated  with  significant  healthcare-related 
costs. Nutritional support, addressing the specific needs of this patient group, is required 
to help improve prognosis, and reduce the consequences of cancer-associated nutritional 
decline.31
                 There exists a relationship between malnutrition and poor prognosis of 
patients with acute lymphoblastic leukaemia . It has been shown that undernourishment 
is  an adverse prognostic factor in the outcome of treatment of patients with ALL in 
malnourished children. Due to diminished bone marrow reserve, these children receive 
approximately 50% of the optimal doses of so-called "maintenance" chemotherapy, thus 
leading to frequent bone marrow leukaemic relapses and hence a shortened disease-free 
survival.32
                   In a study done in Spain in 43 patient ,many variables including age, sex 
,WBC at  diagnosis,  FAB  morphology,  CALLA/CD 10  reactivity  of  the  blast  cells, 
lymph  node,  liver  or  spleen  enlargement,  site  of  treatment  and  malnutrition  were 
analyzed  in  the  outcome  of  treatment.  Of  these  variables  only  malnutrition  had  a 
significant  impact  on  survival.  Undernourished  children(n  =  16)  had  a  significantly 
worser outcome than well nourished children(n=27). The 5 year survival rate was 83% 
for well nourished children and only 26% for undernourished children( p < 0.001). Bone 
marrow relapses presented more in the undernourished than the well  nourished.  The 
doses of maintenance chemotherapy had to be reduced in 68% of undernourished and 
10% of well nourished children. It has been seen that those with a mild to moderate 
degree of undernourishment do better than those with severe forms of malnutrition (2 
year-DFS was 50% and 25% respectively, p less than 0.02), but significantly worse than 
those with normal nourishment status (5 year DFS 83%).9
                   In another Mexican  case control study, the effect of severe malnutrition on 
the mortality of 17 children with ALL during the initial induction-to-remission phase of 
the treatment was studied. These 17 cases 
were  compared  with  76  controls  who  had  survived   the  phases  of  induction  and 
consolidation.   It  was found that the chance of dying during the initial  phase of the 
treatment  was  2.6  times  higher  in  undernourished  children  with  ALL than  in  those 
children with normal nourishment status. The risk of death increased with the severity of 
undernourishment (p = 0.04).33
                    In  a study in Guatemala, some degree of nutritional depletion was seen in 
up to 54% of newly diagnosed children with acute lymphoblastic leukemia. Nutritional 
status was determined by arm anthropometry (mid upper arm circumference and triceps 
skin fold thickness) .Deaths due to abandonment of therapy and treatment failure were 
more common in under-nourished than in well-nourished children.34
                   Undernourishment is an adverse prognostic factor in the outcome of 
treatment of patients with ALL. Malnourished children, due to their diminished bone 
marrow  reserve,  receive  approximately  50%  of  the  optimal  doses  of  so-called 
"maintenance" chemotherapy, thus leading to frequent bone marrow leukaemic relapses 
and  a shortened disease-free survival. 
                     The  delivery of sub-optimal doses of myelosuppressive maintenance 
chemotherapy is by itself, an adverse prognostic factor in the outcome of treatment of 
children with ALL.
c
                     In another Mexican study it has been seen that five year disease free-
survival was 65% and 7% for children receiving either optimal and sub-optimal doses of 
maintenance chemotherapy (p less than 0.001) respectively . Accordingly, suboptimal 
doses of chemotherapy were delivered mainly in undernourished children, due to the 
abnormally low bone marrow reserve . The degree of undernourishment is related to the 
prognosis and also the changes in the nutritional status along with the anti-leukemic 
chemotherapy, have an impact on the prognosis.35
                   The nutritional status of a cohort of children treated for acute lymphoblastic 
leukemia was studied  in Cuba. The study involved 49 children admitted to a single 
center  and  treated  with  a  Berlin-Frankfurt-Munster-based  protocol.  Nutritional 
assessment included measurements of height,  weight,  body mass index and skin-fold 
thickness,  at diagnosis, after the intensive phase of treatment and at the end of therapy. 
There were no statistically significant differences between the results at diagnosis, after 
intensive therapy and at the end of treatment.36
                 Malnutrition has a negative impact on treatment outcome of hospitalized 
patients and results in increased morbidity and mortality in ALL patients. Malnourished 
patients have up to 20 times more complications than well- nourished patients.8.  The 
effects of malnutrition 
on patient outcomes are dramatically demonstrated in morbidity and mortality studies. 
                In a study done in Mexico on 500 patients with ALL in which 376(75%) were 
well nourished and 124(25%) were malnourished, the 5 year survival for well nourished 
was 59% compared to 26% in undernourished children .The relative risk of dying was 
1.8 times higher for  undernourished than the malnourished.  The correlation between 
malnutrition and compromised treatment was 0.92. Malnutrition might be included as an 
adverse prognostic factor in acute lymphoblastic leukemia .37
               A few studies have shown no relationship between malnutrition and the 
outcome of ALL. A study was performed in a cancer centre in Lahore. One hundred 
patients with ALL below the age of 14 years were included in this study.They were 
treated as  per  guidelines of  the BFM protocol.  Patients  were classified according to 
Waterlow classifications of malnutrition (1976). Group-I, as Undernourished children 
(UNC) and Group-II as wellnourished children (WNC). Percentages in both groups were 
found out with respect  to total expired, relapses and completed treatment.In Group-I 
(UNC) 44.5% completed treatment and are alive, 9.5% relapsed and 46% expired. In 
Group-II  (WNC) 59.5% completed  treatment  and are  alive,  5.5% relapsed and 35% 
expired. There was no 
statistical difference in the survival between the WNC and the UNC(p=0.791).38
                 A  study was done at the National Institute of Paediatrics, Mexico  on 100 
patients  with ALL..  The study aim was to  correlate  malnutrition and early  death in 
children  with  acute  lymphoblastic  leukemia.  An  analysis  included  clinical  and 
laboratory parameters as well as co-morbidity factors. Forty patients were standard risk 
and 60 were high risk.  Malnutrition.(p =1)  and poverty(p = 0.5)  had no role  in  the 
outcome of the disease.39
                  According to a study in United Kingdom done on 78 children with ALL, 
Reilly et al, reported that weight for height does have an influence on outcome in ALL, 
but  the  mechanism is  unclear  and  the  finding  requires  confirmation  by  large  scale 
prospective studies.(41)
Chemotherapy and bone marrow reserve:
                 Haematopoietic toxicity is often a side effect of cytotoxic chemotherapy. The 
degree of aplasia and rapidity of count recovery following chemotherapy are indicative 
of bone marrow reserve. Patients who have a normal bone marrow function will recover 
from chemotherapy induced cytopenia relatively rapidly. In contrast patients 
with poor bone marrow reserve will possibly have  prolonged period of aplasia.42
                  The degree and duration of toxicity varies according to the agent used, dose 
and rate of administration.  43.Bone marrow cells are particularly sensitive to damage 
inflicted by alkylating agents. Antimetabolites cause a decrease in granulocyte counts 
within 7 days that lasts no longer than 21 days. The effect of cytotoxic agents on bone 
marrow may be felt after many years .
Factors Affecting Bone Marrow Reserve
The ability of bone marrow to withstand cytotoxicity is directly related to bone marrow 
reserve and to the presence of functional stem cells 44,45. The degree of myelosupression 
depends not only on the particular agent used but also on its dosing, amount of exposure 
and  scheduling.  The  exact  mechanism  by  which  different  chemo-therapeutic  agent 
achieve  myelotoxicity  is  not  fully  understood.In  vitro  and  vivo  data  indicate  that 
decrease in bone marrow reserve is associated with a decrease in stem cells repopulating 
ability. Severe decrease in peripheral blood count, marrow cellularity, stem cell content, 
self-renewal capacity and long term survival was seen in mice treated with drugs that are 
toxic  for  stem  cells.  Different  patient  populations  respond  differently  to  the  same 
chemotherapy.
c
Malnutrition and Bone marrow reserve  
Protein-calorie malnutrition (PCM) also known as protein-energy malnutrition is defined 
by the World Health Organisation (WHO) as being “ a group of pathological conditions 
that is a result of a lower ingestion, in various proportions, of protein and calories. This 
occur  more  frequently  in  children   less  than  five  years  of  age  and  is  commonly 
associated with infection.46
Malnutrition  may  originate  from  the  deficiency  or  absence  of  any  nutrient.  The 
establishment and severity of a state of malnutrition depends on the cause, intensity and 
duration of nutritional deficiency. It can be caused by (i)  an inadequate diet (ii)  by 
deficiency in gastrointestinal absorption (iii) deficient ingestion or increase in demand, 
(iv) an excessive excretion of nutrients. 
Protein-calorie malnutrition (PCM) is usually  found in children,  the elderly,  patients 
suffering from neoplasia or chronic disease, patients undergoing chemotherapy, or even 
patients  under  parenteral  nutrition.  PCM  presents  a  wide  spectrum  of  signs  and 
symptoms that are a result of not only the cause(s) that led to malnutrition, but also of 
the  different  degrees  of  protein  or  carbohydrate  deficiency.   The  implications  of 
modifications of the haemopoietic environment in malnutrition states are still obscure, 
however, they seem to be responsible for inefficient 
haemopoiesis, especially inefficient myelopoiesis, and they seem to be irreversible over 
the short term
Factors affecting haemopoiesis –The Physiology
Blood,  as  a  tissue  is  characterised  by  (i) its  high rate  of  renewal,  taking into 
account that its mature cells present a relatively short lifetime in circulation;47 and (ii) its 
flexibility and ability to adapt to different physiopathological conditions. 
Physiologically, in human adults, haemopoiesis occurs in the bone marrow. The constant 
production  of  cells  depends  on  the  microenvironment  of  the  marrow,  an  organised 
structure that regulates the physiology of the haemopoietic stem cells.48,49,50
               
                  The microenvironment is constituted by haemopoietic cells in different states 
of maturation, stromal cells (reticular cells, macrophages, endothelial cells, adipocytes), 
by  an  extracellular  matrix  (ECM)  and  by  soluble  substances,  51,52,53  in  what  is  a 
compartmentalised,  dynamic  structure,  that  in  addition  to  supplying  parenchymal 
support  for  the  haemopoietic  cells,  provides  a  "biochemical  environment"  that  is 
fundamental for their proliferation, differentiation and maturation. 
Regulatory  factors  that  make  up  inductive  microenvironments  are  considered  to 
exist.54,55,56
                  
                     Haemopoiesis is influenced by several stimuli that act at different levels in 
the process. For this reason, cell-cell and cell-stroma interactions that occur in both the 
haemopoietic inductive microenvironment and other locations must be considered.57 As 
should  the  action  of  the  different  growth  factors  and  cytokines,  hormonal  action  - 
especially  that  of  the  estrogens,  androgens,  thyroid  hormones,  corticosteroids  and 
epinephrine,  plasmatic  and  cellular  mediators  of  the  inflammatory  response  and, 
obviously, the nutritional state of the individual.58,59,60 
Malnutrition and Erythropoiesis: Anaemia
                    The haemopoietic tissue, like all tissues that present a high rate of renewal 
and cellular proliferation, has a high demand for nutrients. The sheer need for protein by 
the  process  of  haemopoiesis  could  in  itself  justify  the  occurrence  of  anaemia  and 
leucopenia which are frequently encountered in malnourished individuals. 
                  PCM is a syndrome in which anemia together with multivitamin and mineral 
deficiency may be present. According to Vilter 
(1975),  children with typical  PCM present  normochromic,  normocytic anaemia,  with 
haemoglobin levels that lie between 8 and 10 g/dL and normal medullary erythropoiesis, 
or a discretely hypoplastic marrow with fatty infiltration.61
Malnutrition and Leucopoiesis:
                      Protein malnutrition induces structural alterations in lymphoid organs, 
especially in thymus-dependant areas.62,63,64,65 Protein deficiency leads to lymphopenia, 
thymus, spleen and lymph node involution, which is particularly intense in the thymus 
and spleen.66,67,68,69,70 Aschkenasy  (1966b)  reported  atrophy of  the thymus and lymph 
organs,  with  a  pronounced  reduction  in  cellularity,  especially  in  thymus-dependant 
areas. 
                    The different lymphocyte populations seem to be affected by malnutrition 
differently:  in  thymus-dependant  areas,  there  is  a  reduction  in  the  number  of  T-
lymphocytes, especially the CD4+ population, whereas the number of B-lymphocytes in 
the spleen, lymph nodes and blood remain normal.
                  Existing data on humoral response are conflicting, which makes definitive 
conclusions hard to reach.62 The concentrations of IgA, 
IgG and IgM can be,  increased,71, or normal or decreased.72 IgE is found at a higher 
concentration in malnourished children.73 
                   It has been shown that though immunoglobulin concentrations may seem to 
be normal in malnutrition, functional studies involving B-lymphocytes indicate that the 
type and intensity of a response to various antigens is altered.
Febrile neutropenia:
       Fever is the principle sign of infection in neutropenic patient and frequently 
may  be  the  only  evidence  of  infection.  The  pattern  of  fever  in  neutropenia  is  non-
specific and not pathognomonic of any type of infections or non-infectious process and 
can  be  suppressed  by  the  antipyretic  effects  of  drugs  such  as  corticosteroids. 
Neutropenia, resulting from cytotoxic chemotherapy is the most common risk factor for 
severe  infections  in  hematological  malignancies.  The  duration  of  neutropenia  also 
contributes significantly to the risk of serious infections. This risk is significantly greater 
with  a lower neutrophil counts, such that 100% patients with ANC <100 cells/microl 
lasting  3  weeks  or  more  develop  documented  infections.  The  prompt  initiation  of 
empirical antibiotics in febrile neutropenia has been the most important advance in the 
management of the immunocompromised host. 
m
                   
                     Fever is associated with malignancy and is a common problem in cancer 
patients When fever appears, a series of diagnostic and therapeutic measures must be 
taken even if precise knowledge of the cause of the infection is lacking. Fever can be 
caused by infection or by the cancer itself through tumor-related necrosis, hemorrhage 
or pyrogens. Infection is the commonest cause, however. Bacterial and fungal sepsis can 
coexist  and  the  bacteremia  can  overshadow  the  more  difficult  to  determine  fungal 
infections.
Definition of febrile and neutropenia
                         The consensus guidelines from the immunocompromised host society 
state  that  a  single  oral  temperature  of  38.5  C  or  more,  or  the  occurrence  of  three 
temperatures of 38 C or more within a 24hours period, taken at least 4hours apart, is 
defined  as  fever  in  a  neutropenic  patient.  Neutropenia  is  defined  as  an  absolute 
neutrophil count (polymorphonuclear cells plus band forms) of 500/ml or less. From a 
practical  stand point  patients  with ANC between 500 and 1000 cells/ml  and rapidly 
falling  ANC  because  of  chemotherapy  are  considered  to  be  at  risk  for  febrile 
neutropenia.74
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                      The criteria of febrile neutropenia should be defined and rigidly adhered to as a 
signal for the initiation of empirical antibiotic therapy , which plays an important role in 
reducing infection related morbidity and mortality in neutropenic patient with fever.
Impaired host defences in haematological malignancies :
                  Patients with hematological malignancies are immunocompromised as a 
result of the underlying malignancy or due to the therapeutic interventions employed to 
manage  it.  Some  malignancies  are  associated  with  specific  immune  defects  that 
predispose to infections with particular pathogens . Patients with acute leukemia have 
increased risk of severe gram-negative bacterial infections as a result of quantitative or 
functional  neutropenia.  Patients  with  chronic  lymphocytic  leukemia  and  multiple 
myeloma  are  susceptible  to  invasive  bacterial  infections  from  staphylococci  and 
streptococci  especially  pneumococcus.  Conversely  patients  with  lymphoma  have 
abnormalities  of  the  cellular  immune  system resulting  in  an  increased  risk  of  viral 
infections (e.g. herpes simplex) and fungal infections (e.g. Cryptococcus). 
                 The duration of neutropenia also contributes significantly to the risk of 
serious infections. This risk is significantly greater at lower neutrophil counts, such that 
100% patients with ANC <100 cells/ml lasting 3 weeks or more develop documented 
infections. Qualitative 
defects in neutrophil function have been described in hematological malignancies. These 
include  defects  in  chemotaxis,  phagocytosis,  bactericidal  capacity,  and  absence  of 
respiratory burst that accompanies phagocytosis. 
Febrile neutropenia and malnutrition:
                     The incidence of febrile neutropenias is clearly more in malnourished 
children than in normally nourished children. This is mainly due to diminished bone 
marrow reserve seen in undernourished children.
                    In a study done in Maulana Azad Medical college,New Delhi, the 
nutritional  status  of  44  children  with  newly  diagnosed  ALL   was  evaluated  by 
anthropometric, hematological and biochemical parameters before initiating therapy and 
response to therapy was assessed during follow up.  Malnutrition was seen in 56.8% 
children by weight for age criteria. Complications like febrile neutropenia and bleeding 
were more in the malnourished group.the incidence of febrile neutropenia was 28% in 
the  well  nourished  group  when  compared  to  32%  in  the  malnourished  group.  A 
statistically  significant  higher  incidence  of  infection  was  seen  in  the  malnourished 
group75
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                    In another study done in Tata Memorial hospital ,Mumbai on 530 patients 
with ALL from 1986 to 1993, it was shown that nutritional status could be relevant to 
toxic death, and there was some evidence that height for age and weight for age had a 
greater impact on toxic death than on disease progression. Patients with height for age 
and weight for age patients below the median for each had a greater risk of dying from 
toxicity (P = 0.049 for height for age and P = 0.023 for weight for age). Such patients 
also  had  an  approximately  2.6-fold  greater  risk  of  dying  from  toxicity  than  from 
progressive disease.76
                   Chemotherapy dose modifications—delays of the next cycle and/or dose 
reductions—are another common consequence of neutropenia and are implemented due 
to a slow recovery of the bone marrow after a previous course of chemotherapy. Recent 
practice pattern studies have shown the extent to which community oncologists delay 
and  reduce  the  doses  of  the  chemotherapy.  In  addition  to  the  direct  effects  of 
neutropenia on the risk of infection and quality of life, there is evidence that neutropenia 
is associated with exacerbations of other adverse effects of chemotherapy. Whether the 
occurrence of neutropenia predicts the occurrence of other adverse events or whether 
neutropenia itself has a causal role in these events is not clear. 
JUSTIFICATION OF THE STUDY
                   Acute lymphoblastic leukemia is the most common malignancy in childhood 
.it accounts to ¼ th of all childhood malignancy .Children with ALL have an overall 
chance  of  survival  of  80%  in  western  countries  and  60%  in  developing  countries. 
Despite significant advances in supportive care during last few years, infection remains 
the  major  cause  of  morbidity  and  death.  These  results  from combination  of  factors 
1)limited supportive care resources in hospital 2)extensive disease at diagnosis 3)poor 
socioeconomic factors 4)malnutrition. Malnutrition has been cited as an important cause 
of morbidity in these children. Undernourished children do poorly as compared with 
well nourished children because of reduced bone marrow reserve ,thus making necessary 
delivery of suboptimal doses of chemotherapy.
This  proposed  study  is  designed  to  determine  the  morbidity  and  outcome  of 
therapy in undernourished children with ALL.
t
 AIM & OBJECTIVES  
To determine the morbidity and mortality pattern amongst children who have received 
the treatment for ALL & impact of nutritional status on the morbidity &outcome of the 
therapy
STUDY DESIGN:
Retrospective cohort study( serial data analysis) 
Consent form:
 Institutional consent was obtained to retrieve data
MATERIALS AND METHODS:
This study was carried out in the hematology unit of Institute of child health. Data was 
retrieved from the case records of Pediatric case sheets. Children who were started on 
treatment from January 1st 2000 to December 30th 2006  were the subjects in the study. 
All these children were treated on the BFM protocol 
201 children with ALL were studied  
Inclusion criteria:
All children who opted for treatment for ALL during the year January 2000 –December 
2006
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Exclusion criteria:  
Patients who presented with relapsed disease. 
Children treated on a different protocol 
No of patients: 201 patients were studied
METHODOLOGY : 
                  Data and diagnosis of patients registered in the Pediatric hematology  clinic 
was maintained . The file number of children with ALL between the period January 
2000 and December 2006 were recorded and the files were retrieved from the medical 
records department of Institute of health child. The relevant information were extracted, 
and recorded on a predesigned profoma. Particular emphasis was laid on extracting the 
following information  
               - Demographic profile, symptomatology, clinical features, height, weight, 
investigations, treatment, follow up and outcome. The nutritional status was determined 
by the WHO standards  ..The data was analysed subsequently. Data concerning morbidity 
during treatment was recorded27. This includes 
Need for blood transfusion 
Need for platelet transfusion 
N
No of children had febrile neutropenia 
Any infection during the treatment 
Relapse 
Mortality 
The date of last evaluation of the child was the end point 
Nutritional status: 
The nutritional status of the child was assessed by weight for age and based on the WHO 
standards the study group was classified as well nourished & undernourished
Weight less than 2  standard deviation(<-2 z) were classified as undernourished 
Weight more  than 2 standard deviation as normal nourished 
Febrile neutropenia:
Febrile neutropenia refers to the clinical presentation of fever( one temperature > 
38.5 C or three readings > 38 C but less than <38.5 C per 24 h) in a neutropenic patient 
with an uncontrolled neoplasm involving 
the  bone  marrow or  more  usually  in  a  patient  undergoing  treatment  with  cytotoxic 
agents.79
Infections :
 The  number  of  children  who  had  infection  was  documented  which  includes 
pneumonia ,hepatitis  ,HbsAg positive patients  ,meningitis,  urinary tract  infections & 
sepsis  
sStatistical analysis:
The mean and standard deviation of all quantitative parameters was calculated 
Percent occurrence rate (Frequency) in respect of different morbidities experienced by 
the sample subjects was calculated. 
Chi  square  test  was  applied  to  quantify  extent  of  intergroup (well  nourished versus 
undernourished) differences.
By logistic regression analysis ,independent predictors of outcome was calculated 
\
\
RESULTS:
Total no of children enrolled in this study was 201.
Age distribution :
Mean age at presentation was 5.8 years range (4 months -12 years)
AGE  (Years) NO OF CHILDREN PERCENTAGE
<1 11 5.5%
1-5 94 46.8%
>5 96 47.8%
201 100%
Sex distribution:
                              MALE                    FEMALE
140 61
69.7% 30.3%
 In the present study, 69.7% were males and 30.3% were female .the difference was 
statistically significant with p valve 0.003.
Mean age at presentation for boys: 6.1 yrs
Mean age at presentation for girls:  5.5 yrs
M
Age- sex distribution:
AGE
MALE
FEMALE
< 1 YEAR
8(72.7%)
3(27.2%)
5 YEAR
58(61.7%)
36(38.2%)
>5YEAR
74(77%)
22(22.9%)
In the present  study,  of the 11 children below 1 year,72.7% were males and 27.2% 
females. Among the children between 1 – 5 years,61.7% males and 38.2% females .and 
> 5 years ,77% males and 22.9% females .in all age groups ,males were predominant  .
>
Nutritional status:  Of the 201 children analysed, 91(45.3%) were undernourished as 
per WHO standards(weight for age < 2 Standard deviation) and 110 (54.7%)were well 
nourished.
             UNDERNOURISHED           WELL NOURISHED
                      91                        110
                      45.3%                       54.7%
Age versus nutritional status
As per WHO standards, 63.6% of children < 1 yr were well nourished and 36.3% were 
undernourished. In age group between 1 – 5 yrs, 58.5% were well nourished and 41.4% 
were undernourished. Above 5 yrs ,50% undernourished and 50% well nourished
NUTRITIONAL STATUS
< 1 YEAR 1– 5 YEAR >5 YEAR
WELL NOURISHED 7(63.6%) 55(58.5%) 48(50%)
UNDERNOURSISHED 4(36.3%) 39(41.4%) 48(50%)
P valve :0.414
P
Sex  versus  nutritional  status:  Of  the  total  61  females,  majority  (52.45%)  were 
undernourished as  against  47.54% well  nourished .In  male  population,  only  42.14% 
were  undernourished  and  57.85%  were  well  nourished.  There  was  no  statistical 
significance between two groups with p valve 0.176 
MALES FEMALES
Well nourished 81(57.85%) 29(47.54%)
Under nourished 59(42.14%) 32(52.45%)
3
Symptom –diagnosis interval ;
The mean symptom diagnosis interval (SDI) was 20.67+14.801days. The range was 5 to 
90 days. The mean SDI in the WN group was 19.84+13.879 days and 21.67+15.865 
days  in  the  UN group.The  difference  between  the  two  groups  was  not  statistically 
significant .(p =0.383)
NOURISHMENT
MEAN
SYMPTOM-DIAGNOSIS
INTERVAL
                
              WELL NOURISHED
             
                           19.84+13.879
              
             UNDERNOURISHED
          
                           21.67+15.865
PTotal  leucocyte  count  at  admission:  The  mean  TLC   at  admission  was 
38679.60+82105.955.There  were  85  (42.2%)   children  with  a  TLC  of 
<10,000;73(36.3%) with a TLC between 10,000 -50,000  ; 31(15.4%) children with a 
TLC  of 50,000-100,000  and 12 (6%) children with TLC of > 100,000.
The ratio of WN and UN  children in all 3groups was analysed. In children with TLC 
<10000, 56.5% were WN and 43.5% were UN. In children with TLC between10,000 
and  50,000  ,50.7  %were  WN  and  49.3%   were  UN.   In  children  with  TLC 
50,000-1,00,000 ,64.5% were WN and 35.5% were UN & in children with TC >100,000 
50% were undernourished & 50% well nourished. There was no statistical difference 
between the two groups (p =0.456) 
TLC TOTAL WELL 
NOURISHED
UNDERNOURISHED
<10000 85 48(56.5%) 37(43.5%)
10000-5000
0
73 37(50.7%) 36(49.3%)
50000-1000
00
31 20(64.5%) 11(35.5%)
>1,00,000 12 6(50%) 6(50%)
6Haemoglobin at admission:
The mean haemoglobin level at admission was 6.924+4.34 g/dl.
 The mean haemoglobin in well nourished children is 7.16+5.93 as against 6.72+2.31 g/
dl..There was no statistical difference between the UN and WN children with p valve of 
0.425
.
NUTRITIONAL STATUS
Hemoglobin  (g/dl)  mean  /  standard 
deviation
WELL NOURISHED 7.162+5.9396
UNDERNOURISHED 6.727+2.3132
Of the 91 undernourished children ,37.36% had Hb level < 5 g/dl,34.06% had Hb level 
between 5 – 8 g/dl, 27.47% had Hb between 8 -11 g/dl and 0.01% had more than 11g/dl. 
Among the well nourished children, 22.72%had Hb level of less than 5 g/dl,40% had 
between 5 to 8 g/dl, 31.80% had 8-11 g/dl and 5 % of them with Hb valve of more than 
11 g/dl  
1
 LEVELOF 
HEMOGLOBIN
UNDERNOURSHED WELL NOURISHED
<5 34(37.36%) 25(22.72%)
5-8 31(34.06%) 44(40%)
8-11 25(27.47%) 35(31.80%)
>11 1(0.01%) 6(5%)
No of children presented  with severe anemia on admission:
< 5 g/dl >5 g/dl
WELL NOURISHED 25 85
UNDERNOURISHED 34 57
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Platelet count at admission:
The  mean  platelet  count  was  43,833.33+65,167  /cu  mm  ,range  between 
1000-3,24000/cu  mm.  On  analysing  the  severity  of  thrombocytopenia  based  on 
nutritional status.
Of  the  91  undernourished  children,46.15%  had  platelet  count  <20,000,46.15%  had 
platelet count between 20,000-1 lakh &7.7% had platelet count >1 lakh. Among well 
nourished  children,  55.5%  had  platelet  count  <  20,000  ,33.6%  had  platelet  count 
between 20,000-1 lakh and 10.9% had platelet count >1 lakh  
PLATELET COUNT WELL NOURISHED UNDERNOURISHED
<20,000 61(55.5%) 42(46.2%)
20,000-1,00,000 37(33.6%) 42(46.2%)
>1,00,000 12(10.9%) 7(7.7%)
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X RAY FEATURES:
On evaluation  of  radiological  features,  156  (77.6% )had  normal  x  ray,24(12%)  had 
leukemic knee deposites  ,17(8.5%) had mediastinal widening ,2 (1.5 %) had osteolytic 
changes and only 1(0.5%)had cardiomegaly
X RAY FINDING NO OF CHILDREN PERCENTAGE
NORMAL 156 77.6%
LEUKEMIC
KNEE  DEPOSITES
24 12%
MEDIASTINAL WIDENING 17 8.5%
OSTEOLYTIC LESIONS 2 1.5%
CARDIOMEGALY 1 0.5%
0
USG  findings:On  evaluating  USG  features,majority  had  hepatosplenomegaly 
(38.8%  ),followed  by  only  hepatomegaly  in  24.9%  children,22.8  %  had 
hepatosplenomegaly with paraaortic nodes,8.9%had renomegaly,0.49%had bowel wall 
thickening &uterine enlargement only 7% had normal USG.
USG FINDING NO OF CHILDREN PERCENTAGE
HEPATOMEGALY 50 24.9%
HEPATOSPLENOMEGALY
70 38.8%
HEPATOSPLENOMEGALY
PARAAORTICLYMPH NODES
46 22.8%
RENOMEGALY 18 8.9%
BOWELWALL THICKENING 1 0.49%
RENAL CALCULI 1 0.49%
NORMAL 14 7%
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Morbidities during therapy:Requirement of PRBCs transfusions:
NOURISHMENT
PRBC transfusion
(mean/standard deviation)
UNDERNORISHED 1.88+0.687
WELLNOURISHED 1.66+0.654
P  valve  significance  (p  =0  .020)Each  Undernourished  child  had  a  requirement  of 
1.88+0.687 blood transfusions at the time of admission as against 1.660+0.654. in well 
nourished child. The statistical difference between the two groups is significant with a p 
value of 0.020.(p <0.05)
Requirement of platelet transfusion:
           
               NOURISHMENT
     PLATELET TRANSFUSION
    (mean/standard deviation)
            UNDERNOURISHED                     2.24 +0.877
             WELL NOURISHED                    1.94+0.725
P value significance (p=0.012)
Each  undernourished  child  had  a  requirement  of  2.24+0.877  platelet  transfusion  as 
against 1.94+0.725 in well nourished child.The statistical difference between two groups 
is significant with a p value 0f 0.012
FEBRILE NEUTROPENIA: 
             77 children in the study population had an episode of febrile neutropenia which 
accounts  to  38%.  On evaluating  based  on  their  nutritional  status  ,  49  children  had 
developed febrile neutropenia  in undernourished children as against 28 children had 
febrile neutropenia in wellnourished children  with significant p value of 
0.00007
UNDER NOURISHED(91) WELL NOURISHED(110)
FEBRILE NEUTROPENIA 49(53%) 28(28%)
 INFECTIONS:  Of  the  total  201  children  ,129(64%)  children  developed  significant 
infection  during  the  course  of  the  treatment  .  The  following  were  the  infection 
encountered during the course of the therapy
UNDERNOURISHED WELL 
NOURISHED
P value
INFECTIONS 62(68.1%) 67(60.9%) 0.479
PNEUMONIA 15(16.5%) 10(9.1%) 0.196
TUBERCULOSIS 1 - 0.270
HBsAg 11(12.1%) 10(9.09%) 0.10
MENINGITIS 5(5.5%) 7(6.4%) 0.450
SEPSIS 14(15.3%) 5(4.5%) 0.0176
UTI 6(6.3%) 7(6.5%) 0.542
HIV 2 1 0.453
Chicken pox 3 1 0.227
Herpes zoster 2 2 0.847
HEPATITIS 18(19.7%) 22(20%) 0.229
URINARY TRACT INFECTIONS:
ECOLI KLEBSIELLA PSEUDOMONAS
WELL NOURISHED 4 3 -
UNDERNOURISHED 3 2 1
TOTAL 7 5 1
The  commonest  organisms  encountered  in  urinary  tract  infection  is  e.coli 
(53.84%),followed   klebsiella  oraganism in  38.46%  and pseudomonas  in  7.6  % of 
children 
c
SEPSIS;
ECOLI KLEBSIELLA STAPYLOCOCCUS PSEUDOMONAS CANDIDA
UN-N 3 1 4 2 4
WELL 
N
- 1 1 - 2
The  commonest  infection  encountered  in  sepsis  was  candida(33.3%),followed  by 
stapylococcus(27.7%),ecoli (16.6%)&klebsiella(11.1%).
@OUTCOME: 
Of  the  201  children  studied  in  the  present  study,  only  46  children  (22.88%)  are 
survivors,52 (25.87%)childre relapsed,52 (25.87%) of them died and 51(25.37%)were 
defaulters
OUTCOME NO OF CHILDREN PERCENTAGE
WELL 46 22.88%
RELAPSE 52 25.87%
DIED 52 25.87%
DEFAULTER 51 25.1%
OUTCOME PREDICTORS
Age:
AGE WELL RELAPSE DIED DEFAULTER
<1 YR 1(9.1%) - 6(54.5%) 4(36.4%)
1-5 YR 26(27.7%) 20(21.3%) 25(26.6%) 23(24.5%)
>5YR 19(19.8%) 32(33.3%) 21(21.9%) 24(25%)
The percentage of children who survived among <1 year,1-5 yrs and > 5 years were 
9.1%,27.7% and 19.8% respectively. The percentage of relapsed  children between 3 
groups were 0%,21.3% and 21.9%respectively and the percentage of death between the 
three  groups  were  54.5%,26.6%  and  21.9%  respectively  .There  was  statistical 
significance between the groups with p valve of 0.049
s
OUTCOME OF CHILDREN LESS THAN 1 YEAR:
On analysing the outcome of children < 1 yr and >1 yr .the percentage of death was high 
in children less than 1 yr accounting to 54.5% and in children 1 yr ,percentage of death 
was 24.2%. the difference in the outcome was statistically significant with p valve of 
0.014  
WELL RELAPSE DIED DEFAULT
< 1 yr 1 - 6 4
>1 yr 45 52 46 47
4
SEX :
WELL RELAPSE DIED DEFAULT
MALES 34 39 30 37
FEMALES 12 13 22 14
 
Among  the  females,  only  12(19.7%)children  were  survivors,  13  (21.3%)relapsed,22 
(36.1%)expired  and  14  (23%)were  defaulters  and  among  males  ,34  (24.3%)  were 
survivors,39(27.9%) relapsed ,30 (21.4%)died and 37 (26.4%)defaulters.there was no 
statistical significance between the 2 groups.
P VALUE ;0.185
P
TOTAL LEUCOCYTE COUNT ;
WELL RELAPSE DIED DEFAULTER
< 5000 9(25%) 8(22.2%) 13(36.1%) 6(16.7%)
5000-50,000 30(24.5%) 29(26.2%) 21(20.4%) 35(28.7%)
50,000-1,00,00
0
7(22.6%) 10(32.3%) 8(25.8%) 6(19.4%)
>1,00,000 - 5(16.7%) 10(50%) 4(33.3%)
The outcome of children with TLC <5000 ,5000-50,000,50,000-1 lakh and >1 lakh were 
compared. The difference was statistically significant with p valve of 0.034 .
2.Comparing the outcome of the children with TLC <100,000 to >100,000.
WELL RELAPSE DIED DEFAULT
<100,000 46 47 42 47
>1,00,000 - 5 10 4
4
The outcome of the children with TLC < 1,00,000 and >1,00,000 were compared .the 
difference was statistically significant with p value of 0.013.
d
NUTRITIONAL STATUS & OUTCOME
   NUTRITIONAL
           STATUS WELL RELAPSE DIED DEFAULTE
R
WELLNOURISHED 29(26.4%) 29(26.4%) 27(24.5%) 25(22.5%)
UNDERNOURISHED 17(18.7%) 23(25.3%) 25(27.5%) 26(28.6%)
Among the well nourished children , 26.4% survived ,26.4%relapsed,24.5% died and 
22.5%defaulted  from  therapy.among  undernourished  ,18.7% 
survived,25.3%relapsed,27.5%died  and  28.6%  defaulted  from  therapy.the  difference 
was not statistically significant.  
w
By logistic regression analysis, independent predictors of mortality has been measured,
variables Co-efficient Std error P value Odds ratio 95%CI-LL 95%CI –UL
AGE< 1 YR 1.7243 0.7171 0.0016 5.6089 1.3754 22.8722
SEX -0.8325 0.3602 0.0608 0.4350 0.2147 0.8811
SDI -0.4119 0.5355 0.4417 0.6624 0.02319 1.8920
Hb -0.0095 0.0461 0.8365 0.9905 0.9049 1.0843
TLC 1.3645 0.5186 0.0085 3.9138 1.4164 10.8149
UN/WN -0.0065 0.3432 0.8464 0.9357 0.4775 1.8336
The  factors  that  had  significant  effect  on  the  outcome  were  age  <  1  yr  and  total 
leucocyte count >1 lakh. They had a p value of 0.001 and 0.0085 respectively
l
DISCUSSION:
Mean age at onset: In the present study, the mean age at presentation was 5.8 yrs (range 
of 4 months- 12 years) when compared with the studies below:
Studies Mean age Range
St JUDE children research 
hospital
4 yrs 73% in 2 -9 yrs
Prokop et al in Germany 6 yrs 1-16 years
Ankara,turkey 7.35+38 1-14 yrs
Karachi, Pakisthan 6.5 yrs -
NetajisubbashChandra bose 
hospital ,Kolkata
11yrs 1-25 yrs
Vellore hospital 6 yrs 1-14 yrs
Present study
MEAN  AGE
5.8 yrs
RANGE
4months-12years
Sex disparity:
In the present  study, the glaring male predominance ( 69.7%) was noted.  This male 
preponderance  was  consistent  with  that  seen  in  the  rest  of  the  world  and  our  own 
country as shown below 
STUDIES MALE:FEMALE RATIO
St,Jude children research hospital 3.8:1
Prokop et al in Germany 2.2:1
Karachi,Pakisthan 1.7:1
Tatamemorial hospital/AIIMS,delhi 2.9:1
PRESENT STUDY 2.29:1
Nutritional status: 
In the present study ,  45% of the children were underweight according to the WHO 
standards(Z< 2 SD). This is less than the overall data from other parts of our country. 
The difference in nutritional status between the girls and the boys was not statistically 
significant( p=0.77).
STUDY % of undernutrition at presentation(weight 
for age)
Maulana Azad medical college ,new delhi 56.8%
PGIMER,Chandigarh 52%
Kuala, lumpur 37.3%
Turkey 56.8%
Mexico 37%
Present study 45%
4
Symptom diagnosis interval: 
                The mean symptom diagnosis interval was 20.67+14.80 days. The mean SDI 
in  WN  children  is  19.84+14.80  days  and  21.67+15.865  days  in  UN  children  .The 
difference between the two groups was not statistically  significant  (p= 0.383)
This delay in diagnosis is related to the poor socioeconomic status and low educational 
status. Lack of parental education and little awareness of health issues delay the seeking 
of medical help. In addition, limited knowledge and subsequent late recognition by the 
health care providers in rural areas may delay the referral to higher centre. Consequently 
children have more advanced stage at diagnosis.
Haemoglobin level at presentation;
                  The mean Hemoglobin was 6.924 +4.304 g/dl. The mean Hb in WN children 
was  7.162+5.9396  and  6.727  +2.3132  in  UN  children.The  difference  between  two 
groups was not statistically significant (p ).but the no of children who had hemoglobin 
<5 g/dl  was significantly  high in37.36% UN children as  compared to 22.72%  WN 
children (p 0.0233)
c
Total leucocyte at admission:
study
1 lakh
St Jude hospital
14%
UK
12%
germany
11.3%
Dana farber consortium U.S
10.9 %
Cancer institute chennai
23.2%
Tata memorial hospital
14.6%
AIIMS
18%
PRESENT STUDY >1 LAKH:9.9% >50,000:21.3%
We have 9.9 % children with TLC > 1,00,000 and 21.3% children with TLC >50,000 at 
admission. As compared with other studies, our population had more no of children with 
TLC > 50,000. The difference noted is possibly due to heterogeneity in the population 
and the geography of the country   
a
Morbidities : 
Requirement of blood and platelet transfusion: 
               Each  Undernourished child  had a  requirement  of  1.88+0.687 blood 
transfusions at the time of admission as against 1.660+0.654 in well nourished child The 
statistical difference between the two groups was significant with a p valve of 0.020.(p 
<0.05) 
Each  undernourished  child  had  a  requirement  of  2.24+0.877  platelet  transfusion  as 
against  1.94+0.725  in  well  nourished  child.  The  statistical  difference  between  two 
groups was significant with a p valve 0f 0.012.
Febrile neutropenia:
In the present study, 53% of  undernourished children had febrile neutropenia as against 
25% in well nourished children with p valve significance (0.00007).This observation 
correlates with that of  a  study from Maulana Azad Medical College, Delhi was has also 
shown an higher incidence of febrile neutropenias (32%) in the UN group as compared 
to 28% in the WN group.75  In a study in the USA the mortality rate in children with 
cancer because of febrile neutropenia  given as 3%88.
.
Infections encountered in the study:  
            The following studies has shown that the children with ALL had more no of 
infection as against normal population with significant p valve < 0.01 
STUDY RESULTS  PRESENT STUDY 
FINLAND Respiratory  tract  infection 
(44%)
Pneumonia (12.34%)
Ann  academic  medical 
college ,Singapore
Respiratory tract infection
King abdul  aziz  hospital, 
Saudi Arabia
Hepatitis-80% 
9.8% positive for HBsAg
Hepatitis(19.90%)
HBs Ag 10.94%
Kidwai  ,memorial 
institute , Bangalore
Sepsis  (gram  negative 
bacteria)
Sepsis (9.4%)
Fungalsepsis  (commonest 
sepsis)
In my present study, 64% of the children had significant documented infection.68% of 
undernourished children and 60% of well nourished children had significant infection. 
The  difference  between  the  two  groups  was  not  statistically  significant.  Of  all  the 
documented  infection  ,sepsis  have  occurred  in  more  no  of  children  among 
undernourished as compared 
to  well  nourished  children  the  p  valve  significant.   The  fungal  sepsis  were  the 
commonest documented infection .
Outcome of the study population:
Analysing  the  outcome  in  201  children,  46  (22.88%)  were  survivors,  51 
(25.37%)dropped out,52 (25.87%) expired and 52 (25.87%)  relapsed. 
Prognostic factors:
Age :
Age has remained an independent predictor of outcome. In the present study,  Children 
aged > 1 yr have a better disease free survival than infants (p 0.0414) . Infants and 
adolescents have a less favorable prognosis than children between 1 and 10 years of age. 
However, contemporary intensive treatment regimens have decreased the effect of age. 
In the Nordic series , infants fare worse than older children, but the difference between 
adolescents (>10 years of age) and other children older than 1 year is very slight. In the 
MRC UKALL X and Xa trials, age was an independent prognostic factor in a mixed 
population of children (excluding infants under 1 year of age) and adults .91,92,93,04
In the BFM-90 study, children aged 1-9 years had a favourable outcome. The CCG also 
had a worse prognosis in children aged 10 or more years as compared with younger non 
infants . The same trend has been shown in 
studies  performed  by  many  major  co-operative  study  groups  (POG,  MRC,  SJCRH, 
Italian Association of Pediatric Hematology and Oncology (AIEOP), Dutch Childhood 
Leukemia  Study  Group  (DCLSG),  COALL,  Children  Leukemia  Cooperative  Group 
(CLCG-EORTC) and TCCSG).91,92,93,94
Among the Indian studies, a study from Tata  Memorial Hospital ,  Mumbai , age at 
presentation did  not have a significant effect on the outcome as per the univariate and 
multivariate analyses. 
 At the study done in Cancer institute , Chennai the effect of age was not significant with 
univariate   p  value of  0.16.  in the study done in AIIMS ,  New Delhi  age was non 
significant with p values of 0.1 and 0.2 respectively.8 
Infants with ALL have a very high risk of treatment failure. This is partly related to the 
higher  incidence  of  unfavourable  very  immature  pro  B  –cell  ALL  prototype  and 
presence of mixed lineage gene rearrangements
àsex: The difference in outcomes between males and females was not significant with a 
p  value of 0.892 
study Outcome – girls Outcome – boys
Pui & co workers (1960) 43.1% 31.5%
Pui & co workers (1991-94) 84% 71%
Nordic patients 59% 48%
BFM-90 82% 75%
Present study 27.86% 20.71%
 In contrast to other studies, 27.86%  of the boys were survivors as against 20.17% in 
girl. Indian studies from various centres does not show sex difference in the outcome. 
One reason for  the better  prognosis  for  girls  shown in some studies  because  of  the 
occurrence of testicular relapses among boys, but boys also appear to be at increased 
risk of bone marrow and CNS relapse for reasons that are not well understood. However, 
in clinical trials with high 5-year EFS rates (>80%), male gender is not an adverse risk 
factor.
f
Total  leucocyte  count :  In  our  study  we  found  that  a  high  TLC  at  presentation 
(>1,00,000/cu.mm) have a worse outcome. The difference was statistically significant 
between  children  with  a  TLC  of  <1,00,000/cu.mm  and  those  with   TLC  of  > 
1,00,000/cu.mm(p =0.013).When children with TLC <50,000/cu.mm, 50,000/cu.mm – 
1,00,000/cu.mm  and    >1,00,000/cu.mm  were  compared,  the  outcomes  differed 
significantly(p =0.0384). 
               In a study done in Poland, from 1981 to 1986, in children with ALL an initial 
WBC above 50,000/mm3, achieved significantly worse treatment results than children 
with lower WBC. The 6-year disease-free survival being 33% and 60%. In the Nordic 
study, the 5- year event-free survival (EFS) for children with WBC 50-100x109/L is 
67.3%. The EFS continues to decline with the elevation of the lower cut-off point being 
41.3%   WBC >100x109/L  and 30.2% in WBC > 200x109/L .
               In the multicentric Indian study , it was found that TLC at presentation was not 
significantly associated with toxic death in any of the 3 centres. Conversely TLC might 
be expected to have a greater prognostic significance in populations with lower toxic 
death rates.   The univariate p values for the effect of TLC on Disease Free Survival 
were  0.0002  ,  0.0011  and  0.066  respectively  in  Mumbai,  New  Delhi  and  Chennai 
respectively.8
8
Nutritional status:
             In our study, undernutrition (indicator weight for age) did not influence in the 
outcome in the children with ALL. 
           In a study done in Spain in 43 patients ,undernourished children(n = 16) had a 
significantly worser outcome than well nourished children(n=27). The 5 year survival 
rate was 83% for well nourished children and only 26% for undernourished children( p < 
0.001). 9
              In another Mexican study it has been seen that five year disease free-survival 
was  65%  and  7%  for  children  receiving  either  optimal  and  sub-optimal  doses  of 
maintenance  chemotherapy  (p  less  than  0.001)  respectively  .Suboptimal  doses  of 
chemotherapy  were  delivered  mainly  in  undernourished  children.  They  summarized 
malnutrition to have an adverse impact on survival in ALL..Another Mexican study in 
500 ALL patients has given DFS for WN children to be 75% as compared to 26% in UN 
children.35
               In Pakistan a study done at Lahore on 100 patients with ALL did not show any 
difference in the survival ,38 death and relapse when they compared the UN and WN 
children. A study in Scotland compared BMI to survival.They did not find any evidence 
of BMI being related to the clinical outcome.40
4
                  Though there are multiple studies that stress the importance and poor prognostic 
role of malnutrition at diagnosis in the outcome of patients with  ALL.
          In the Indian collaborative trial nutritional status was not seen to be a risk factor 
influencing outcome and survival. 
SUMMARY:       
201 children with ALL were studied ( registered between Jan 2000 – Dec 2005) 
The mean age of presentation was 5.8 yrs(4 months – 12 yrs) .There was no difference 
between the age of presentation between boys and girls.
The male to female ratio was 2.29:1.
5.4% children were below 1year of age.
45% children were undernourished at presentation as per the WHO standards.
The nutritional status was the same amongst boys and girls.
21.50% children had a presenting TLC of >50,000/cu.mm. and 9.9% had a TLC 
>1,00,000 at diagnosis.
The presenting TLC was similar in the UN and WN groups.
The no of children presented with severe anemia was high in UN as compared to WN (p 
value :0.0233)
The mean SDI was 20.67+14.801days.This was similar in the WN &UN  group.
The morbidity –Requirement of platelet and blood transfusion at the time of admission 
were high in undernourished children as compared to well nourished children .(p 0.020 
and 0.012 respectively )
a
 53% of undernourished children had an episode febrile neutropenia as compared to 29% 
in well nourished children(p 0.0007)
Sepsis was documented in higher no of undernourished children as compared to well 
nourished children (p 0.0176)
Fungal  sepsis were the commonest  infection encountered in undernourished children
In this study,22.88% children are survivors. The difference in survival between the UN 
and WN  group is not significant
 Mortality accounts to 25.87% and relapse accounts to 25.8%
On analysing the prognostic factors , age less than 1 year and TLC > 1,00,000  was 
associated with poor prognosis both by univariate and multivariate analysis with p value 
of 0.014 and 0.0016 respectively
No difference was seen in the mortality rate in the WN and UN group .
 
 CONCLUSION:
 The overall survival in 201 children treated for ALL using the BFM protocol 
was  22.8%.. 
The most important prognostic indicator for outcome is TLC and age.
 Children with a high TLC (>1,00,000/mm3  )have an mortality rate of  50%.
.Children less than 1 year  also had a worst outcome .
Higher incidence of febrile neutropenia and sepsis was seen in undernourished children 
as compared to well nourished children. 
.Nutritional status(indicator weight for age ) did not influence the outcome of the 
children with ALL
cPROFORMA (Annexure  I)
Name : Father’s Education 
H  No.             Mother’s Education 
DOB Urban / Rural 
Sex : 
Date of Diagnosis 
Date of last evaluation 
Age of diagnosis (month) 
Symptoms – Diagnosis interval 
Type of ALL 
Hb at admission 
TLC 
Platelet 
Weight at admission 
Height at admission 
Serum albumin
x ray
USG abdomen
U
Nutritional status  according to WHO  standard charts
Well nourished / under nourished 
Hepatitis /HBsAg  positives 
HIV status (inc both parents)
Date 
Admission 
Blood transfusion (at presentation)
Platelet transfusion (at presentation)
Febrile neutropenia 
Site (focus) 
Blood 
 C/S
Other C/S
Fever without neutropenia 
F
Status last evaluation 
1. Well 
2. Relapsed 
3. Died 
4. Treatment defaulter 
Duration off therapy 
________________months 
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